In Brief: FluMist Influenza Vaccine for Self-Administration
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season. FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2024-10-10
- DOI
- https://doi.org/10.58347/tml.2024.1714c
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00